It has been reported that up to 42% of the population aged over 60 are affected by mild cognitive impairment (MCI) worldwide. This study aims to investigate the prevalence and progression of MCI through a meta-analysis. We searched Embase and PubMed for relevant literature. Stable disease rate (SR), reversion rate (RR), dementia rate (DR), and Alzheimer's disease rate (AR) were used to evaluate the progression of MCI. The prevalence and progression rates were both obtained by reported percentile and indirect data analysis. Additionally, we carried out sensitivity analysis of each index by excluding some studies due to influence analysis with the most publication bias. Effect size (ES) was used to present adjusted overall prevalence (16%) and progression rates including SR (45%), RR (15%), DR (34%), and AR (28%) of MCI. Compared with clinic-based outcomes, MCI prevalence, SR, and RR are significantly higher in community, while DR and AR are lower. Despite significant heterogeneity found among the studies, no publication bias was observed. Age and gender were observed to be associated with MCI, in which age was considered as an impact factor for DR. The strong heterogeneity may result from variations in study design and baselines. Standardized MCI criteria were suggested to systematically evaluate MCI in the future.

Purpose: The study aimed to investigate whether astrocyte pyroptosis, and the subsequent neuroinflammatory response that exerts amyloid β (Aβ) neurotoxic effects, has an effect on endothelial cells, along with the underlying mechanisms. Methods: In vivo, 5 μL of disease venom was injected into the lateral ventricle of APP/PS1 mice for treatment. Pyroptosis was induced by treating astrocytes with Aβ42 in vitro. Small interfering RNA (siRNA) was used to silence caspase-1 and Gasdermin D (GSDMD) mRNA expression. Cell viability was determined using a CCK-8 detection kit. Scanning electron microscopy (SEM), Annexin V/propidium iodide (PI) double staining, RT-qPCR, immunofluorescence, western blotting, and enzyme-linked immunosorbent assay (ELISA) were used to detect cell pyroptosis. The degree of pathological damage to the brain and aortic tissue was assessed by hematoxylin-eosin staining and immunohistochemistry. Results: Aβ42 induced astrocyte pyroptosis dependent on the GSDMD/Gasdermin E (GSDME)/Caspase 11/NLRP3 pathway, releasing large amounts of inflammatory factors, such as TNF-α, IL-1α, IL-1β, and IL-18. Astrocyte pyroptosis caused endothelial cell dysfunction and release of large amounts of vasoconstrictors (ET and vWF). Knockdown of GSDMD reduced astrocyte pyroptosis in the cerebral cortex and hippocampal tissue, decreased the release of inflammatory factors IL-1 β and IL-18, reduced Aβ deposition and tau protein, increased the release of peripheral vasodilator substances (eNOS), and decreased the release of vasoconstrictor substances (ET, vWF), thereby reducing brain tissue damage and vascular injury in APP/PS1 mice. Conclusion: Aβ42 induced astrocyte pyroptosis, while GSDMD knockout inhibited astrocyte pyroptosis, reduced the release of inflammatory factors, and alleviated brain tissue damage and vascular damage in APP/PS1 mice. Therefore, GSDMD is a novel therapeutic target for Alzheimer’s disease.

To evaluate the risk factors for progress of mild cognitive impairment to dementia. This study was based on the epidemiological survey in 2011 (No. PKJ2010-Y26) and contained 441 MCI individuals. Cognitive function was measured by the Mini-Mental Status Examination, clinical dementia rating, and montreal cognitive assessment. The association between demographic characteristics and MCI outcomes were evaluated using single-and multifactor ordered logistic regression analysis models. Of the 441 MCI, 77 progressed to dementia (MCIp: 17.5%, 95% CI: 14.4%-21.6%), 356 remained stable (MCIs: 80.7%, 95% CI: 77.0%-88.4%), and 8 reverted to normal cognition (MCIr: 1.8%, 95% CI: 0.6%-3.0%) at follow-up in 2017. Univariate ordinal regression analysis showed that diabetes (P = .052), marriage (P = .028), worker (P = .069), and manager (P = .075) may be the risk factor for the status of MCI. Multiple ordinal regression results showed that diabetes (P = .049) and marriage (P = .04) significantly affected the cognitive function changes in the MCI patients. Nondiabetics and being married may prevent the progression from MCI to dementia.

Background: Studies conducted outside of China have found that stigma can predict low quality of life, and research in China has shown that stigma has an impact on the quality of life of convalescent patients with schizophrenia. Nevertheless, there is no indepth research on the impact of stigma on the quality of life of patients. Aims: To research the correlation of stigma and the subjective quality of life of persons with chronic schizophrenia in the community. Methods: We adopted a stratified sampling method. General questionnaire, quality of life scale and stigma scale were given to 602 persons with chronic schizophrenia in the community. Results: The mean (SD) value of the Subjective Quality of Life Scale total scores was 32.99 (13.85). The mean (SD) value of the total stigma scores was 43.50 (5.02). After correlation analysis and multivariate stepwise regression analysis, it was shown that the total scores for self‐stigma and each factor were positively correlated with subjective quality of life ( r =0.462, p <0.001), psychosocial factors ( r =0.517, p <0.001), and symptoms and adverse reaction factor scores ( r =0.363, p <0.001), and the correlation coefficients were statistically significant. Conclusions: The higher the stigma of persons with schizophrenia in the community, the lower the subjective quality of life is. This suggests that reduction of self‐stigma should be considered in the improvement of the quality of life of persons with schizophrenia in the community.

Background: Stigma is a barrier to schizophrenia recovery; thus, screening the factors that affect stigma experienced by patients with schizophrenia and exploring the interactions between each factor are critical for improved treatment. The purpose of this study was to demonstrate the relationship between quality of life (QoL), family dynamics, and stigma in patients with schizophrenia.Methods: A total of 447 participants with schizophrenia were recruited in the study, namely, 281 community patients and 166 inpatients. Three scales, Schizophrenia Quality of Life Scale (SQLS), Self-rating Scale of Systemic Family (SSFD), and Stigma Scale for Mental Illness (SSMI), were, respectively, used to evaluate three variables: QoL, family dynamics, and stigma. The correlations between each factor in these three scales were evaluated by Spearman's rank correlation analysis. A mediation model was constructed to investigate whether QoL mediated the relationship between stigma and family dynamics.Results: Correlation analysis revealed that most variables in these three scales correlated significantly with each other. Mediational regression analyses indicated that the degree of stigma was affected by family dynamics; that is, good family dynamics predicted less stigma. Surprisingly, we found that a worse QoL was associated with less stigma, and this led to good family dynamics being related to a worse QoL. These findings further suggested that QoL had a mediating effect on the relationship between family dynamics and stigma.Conclusions: This study suggested that more attention should be focused on the multifactorial influence of stigma on patients with schizophrenia. Integrated and personalized interventions regarding QoL and family dynamics can be tailored for patients with schizophrenia to reduce self-stigma.